The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS) over 12 ...

BMC Neurology Retrospective US Database Analysis of Persistence With Glatiramer Acetate vs. Available Disease-Modifying Therapies for Multiple Sclerosis: 2001–2010 ...

Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The r ...

Glatiramer Acetate Injection had annual sales of US$ 719mn in the United States (IQVIA MAT Mar-2025). The group now has 426 approvals and has so far filed 492* ANDAs since the commencement of the ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information. Marketed under the ...

If someone with multiple sclerosis experiences any symptoms of anaphylaxis after taking glatiramer acetate, they should seek immediate medical attention by going to an emergency room or calling ...

Glatiramer acetate (Copaxone) is considered part of the “platform therapy” for MS. It’s also among the earliest approved disease-modifying treatments. It’s self-administered as a ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling 911 if you experience symptoms of an anaphylactic reaction, FDA warned.

The U.S. Food and Drug Administration (FDA) has issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's Copaxone.